Matthew W B Trotter
Overview
Explore the profile of Matthew W B Trotter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbiati R, Pourdehnad M, Carrancio S, Pierce D, Kasibhatla S, McConnell M, et al.
AAPS J
. 2022 Jan;
24(1):29.
PMID: 35038051
No abstract available.
2.
Ortiz-Estevez M, Towfic F, Flynt E, Stong N, Jang I, Wang K, et al.
BMC Med Genomics
. 2021 Dec;
14(1):295.
PMID: 34922559
Background: Despite significant therapeutic advances in improving lives of multiple myeloma (MM) patients, it remains mostly incurable, with patients ultimately becoming refractory to therapies. MM is a genetically heterogeneous disease...
3.
Abbiati R, Pourdehnad M, Carrancio S, Pierce D, Kasibhatla S, McConnell M, et al.
AAPS J
. 2021 Aug;
23(5):103.
PMID: 34453265
Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent...
4.
Wall M, Turkarslan S, Wu W, Danziger S, Reiss D, Mason M, et al.
NPJ Precis Oncol
. 2021 Jun;
5(1):60.
PMID: 34183722
Despite recent advancements in the treatment of multiple myeloma (MM), nearly all patients ultimately relapse and many become refractory to multiple lines of therapies. Therefore, we not only need the...
5.
Danziger S, McConnell M, Gockley J, Young M, Rosenthal A, Schmitz F, et al.
PLoS Med
. 2020 Nov;
17(11):e1003323.
PMID: 33147277
Background: The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone...
6.
Risueno A, Hagner P, Towfic F, Fontanillo C, Djebbari A, Parker J, et al.
Blood
. 2020 Jan;
135(13):1008-1018.
PMID: 31977005
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. We sought to identify novel patient subgroups through an unsupervised analysis of a large...
7.
Carpio C, Bouabdallah R, Ysebaert L, Sancho J, Salles G, Cordoba R, et al.
Blood
. 2020 Jan;
135(13):996-1007.
PMID: 31977002
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival. Avadomide (CC-122) is a...
8.
Medvedeva I, Stokes M, Eisinger D, LaBrie S, Ai J, Trotter M, et al.
Sci Rep
. 2020 Jan;
10(1):605.
PMID: 31953524
Finding biomarkers that provide shared link between disease severity, drug-induced pharmacodynamic effects and response status in human trials can provide number of values for patient benefits: elucidating current therapeutic mechanism-of-action,...
9.
Danziger S, Gibbs D, Shmulevich I, McConnell M, Trotter M, Schmitz F, et al.
PLoS One
. 2019 Nov;
14(11):e0224693.
PMID: 31743345
Immune cell infiltration of tumors and the tumor microenvironment can be an important component for determining patient outcomes. For example, immune and stromal cell presence inferred by deconvolving patient gene...
10.
Romero J, Ortiz-Estevez M, Muniategui A, Carrancio S, de Miguel F, Carazo F, et al.
BMC Genomics
. 2018 Sep;
19(1):703.
PMID: 30253752
Background: RNA-seq is a reference technology for determining alternative splicing at genome-wide level. Exon arrays remain widely used for the analysis of gene expression, but show poor validation rate with...